UAE approves first oral treatment for non-segmental vitiligo

Yesterday 11:44

By: Azzat Manal

UAE approves first oral treatment for non-segmental vitiligo

The United Arab Emirates has made a significant development in the treatment of non-segmental vitiligo after becoming the first country to officially approve an oral tablet specifically for the condition, according to reports by Gulf News outlets.

The newly approved treatment is available to patients aged 12 and above and represents a potential expansion of therapeutic options for people living with vitiligo. The medication is administered as a once-daily tablet, offering a relatively simple treatment routine compared with some existing approaches.

Vitiligo is a chronic autoimmune skin disorder that causes areas of the skin to lose their natural pigmentation. The condition occurs when melanocytes, the cells responsible for producing melanin, are destroyed or stop functioning properly.

Non-segmental vitiligo is the most common form of the disease and can affect different areas of the body. Although it is not contagious or life-threatening, the visible changes in skin pigmentation can have a considerable psychological and social impact on patients.

The introduction of an oral treatment could therefore provide an additional option for patients who require systemic therapy. A once-daily regimen may also make treatment easier to integrate into everyday life and could help improve adherence.

The UAE's regulatory decision highlights the country's growing efforts to expand access to innovative medicines and strengthen its position in the regional healthcare sector. The approval also reflects the broader progress being made in the development of targeted treatments for autoimmune and inflammatory conditions.

For patients and healthcare professionals, the availability of new treatment options is particularly important because vitiligo can vary considerably from one person to another. Treatment decisions generally depend on factors such as the extent and progression of the condition, the patient's age and the areas of the body affected.

The development also illustrates the growing importance of regulatory innovation in healthcare, as countries seek to provide patients with access to emerging therapies while maintaining appropriate standards for safety and effectiveness.

The UAE's approval could attract further attention from healthcare institutions and pharmaceutical companies as research into vitiligo continues. It may also contribute to broader discussions about improving treatment options and quality of life for people living with the condition.